This statistic shows the results of a survey concerning the payment of dividends by the pharmaceutical industry thanks to the revenues of the innovative treatments reimbursed by the French Social Security in 2016. More than a third of respondents did not at all agree with the idea that the pharmaceutical industry pays dividends to its shareholders with the revenues of expensive innovative treatments reimbursed by Social Security.
Do you agree with the idea that it is normal for the pharmaceutical industry to pay dividends to its shareholders with the revenues of expensive innovative treatments reimbursed by Social Security? *
* The question was formulated by the source as follows: "The prices of some innovative drugs are rising. In France, for example, recently for hepatitis C, treatment at 40,000 euros has led to the selection of patients: it has only been delivered to the most serious cases. For each of the following opinions, say: us if you strongly agree, tend to agree, tend to disagree or strongly disagree. - It is normal for the pharmaceutical industry to pay dividends to its shareholders with income expensive innovative treatments reimbursed by Social Security. "
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
BVA, & CISS. (March 4, 2016). Do you agree with the idea that it is normal for the pharmaceutical industry to pay dividends to its shareholders with the revenues of expensive innovative treatments reimbursed by Social Security? * [Graph]. In Statista. Retrieved November 10, 2024, from https://www.statista.com/statistics/768748/opinions-french-earnings-industry-pharmaceutical-treatments-innovative/
BVA, und CISS. "Do you agree with the idea that it is normal for the pharmaceutical industry to pay dividends to its shareholders with the revenues of expensive innovative treatments reimbursed by Social Security? *." Chart. March 4, 2016. Statista. Accessed November 10, 2024. https://www.statista.com/statistics/768748/opinions-french-earnings-industry-pharmaceutical-treatments-innovative/
BVA, CISS. (2016). Do you agree with the idea that it is normal for the pharmaceutical industry to pay dividends to its shareholders with the revenues of expensive innovative treatments reimbursed by Social Security? *. Statista. Statista Inc.. Accessed: November 10, 2024. https://www.statista.com/statistics/768748/opinions-french-earnings-industry-pharmaceutical-treatments-innovative/
BVA, and CISS. "Do You Agree with The Idea That It Is Normal for The Pharmaceutical Industry to Pay Dividends to Its Shareholders with The Revenues of Expensive Innovative Treatments Reimbursed by Social Security? *." Statista, Statista Inc., 4 Mar 2016, https://www.statista.com/statistics/768748/opinions-french-earnings-industry-pharmaceutical-treatments-innovative/
BVA & CISS, Do you agree with the idea that it is normal for the pharmaceutical industry to pay dividends to its shareholders with the revenues of expensive innovative treatments reimbursed by Social Security? * Statista, https://www.statista.com/statistics/768748/opinions-french-earnings-industry-pharmaceutical-treatments-innovative/ (last visited November 10, 2024)
Do you agree with the idea that it is normal for the pharmaceutical industry to pay dividends to its shareholders with the revenues of expensive innovative treatments reimbursed by Social Security? * [Graph], BVA, & CISS, March 4, 2016. [Online]. Available: https://www.statista.com/statistics/768748/opinions-french-earnings-industry-pharmaceutical-treatments-innovative/
